Анемия у взрослых онкологических пациентов
- Авторы: Телетаева Г.М.1, Дегтярёва Е.А.1, Проценко С.А.1, Латипова Д.Х.1, Семенова А.И.1, Новик А.В.1, Семиглазова Т.Ю.1
-
Учреждения:
- Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова
- Выпуск: Том 30, № 6/7 (2023)
- Страницы: 101-109
- Раздел: Проблема
- URL: https://journals.eco-vector.com/2073-4034/article/view/562820
- DOI: https://doi.org/10.18565/pharmateca.2023.6-7.101-109
- ID: 562820
Цитировать
Полный текст
Доступ предоставлен
Доступ платный или только для подписчиков
Аннотация
Анемия является частым осложнением злокачественного процесса, негативно влияя на качество жизни пациента, а также на результаты противоопухолевого лечения и прогноз заболевания в целом. Патогенез анемии при злокачественном процессе достаточно сложен и обусловлен как наличием самой опухоли, так и проводимым противоопухолевым лечением. В настоящем обзоре обобщены современные представления о причинах и механизмах развития анемии у онкологических пациентов, изложены алгоритм диагностики и ключевые методы коррекции данного состояния.
Полный текст
Об авторах
Гульфия Мидхатовна Телетаева
Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова
Автор, ответственный за переписку.
Email: drteletaeva@yahoo.com
ORCID iD: 0000-0001-9365-8554
к.м.н., врач-онколог отделения противоопухолевой лекарственной терапии
Россия, Санкт-ПетербургЕ. А. Дегтярёва
Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова
Email: drteletaeva@yahoo.com
ORCID iD: 0000-0001-8533-1770
Россия, Санкт-Петербург
С. А. Проценко
Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова
Email: drteletaeva@yahoo.com
ORCID iD: 0000-0002-5026-0009
Россия, Санкт-Петербург
Д. Х. Латипова
Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова
Email: drteletaeva@yahoo.com
ORCID iD: 0000-0002-8906-0370
Россия, Санкт-Петербург
А. И. Семенова
Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова
Email: drteletaeva@yahoo.com
ORCID iD: 0000-0003-4538-8646
Россия, Санкт-Петербург
А. В. Новик
Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова
Email: drteletaeva@yahoo.com
Россия, Санкт-Петербург
Т. Ю. Семиглазова
Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова
Email: drteletaeva@yahoo.com
ORCID iD: 0000-0002-4305-6691
Россия, Санкт-Петербург
Список литературы
- Ludwig H., Van Belle S., Barrett-Lee P., et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004;40(15):2293–306. doi: 10.1016/j.ejca.2004.06.019.
- Knight K., Wade S., Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med. 2004;116(Suppl. 7A):11–26. doi: 10.1016/j.amjmed.2003.12.008.
- Tas F., Eralp Y., Basaran M., et al. Anemia in oncology practice: relation to diseases and their therapies. Am J Clin Oncol. 2002;25(4):371–79. doi: 10.1097/00000421-200208000-00011.
- Dicato M. Anemia in cancer: some pathophysiological aspects. Oncologist. 2003;8(Suppl. 1):19–21. doi: 10.1634/theoncologist.8-suppl_1-19.
- Escobar Alvarez Y., de Las Penas Bataller R., Perez Altozano J., et al. SEOM clinical guidelines for anaemia treatment in cancer patients (2020). Clin Transl Oncol. 2021;23(5):931–39. doi: 10.1007/s12094-021-02580-2. Erratum in: Clin Transl Oncol. 2021;23(10):2192–93.
- Патофизиология: учебник: в 2 т. Под ред. В.В. Новицкого, Е.Д. Гольдберга, О.И. Уразовой. 4-е изд., перераб. и доп. М., 2010. Т. 2. 640 с., илл. [Pathophysiology: textbook: in 2 volumes, Ed. V.V. Novitsky, E.D. Goldberg, O.I. Urazova. 4th ed., revised. and additional. Moscow, 2010. Vol. 2. 640 p., ill. (In Russ.)].
- Кулибаба Т.Г., Пчелин И.Ю., Слепых Л.А. Особенности анемического синдрома у онкологических пациентов. Juvenis Sci. 2018;9:10–6. [Kulibaba T.G., Pchelin I.Yu., Slepykh L.A. Features of anemic syndrome in cancer patients. Juvenis Sci. 2018;9:10–6. (In Russ.)]. doi: 10.32415/jscientia.2018.09.02.
- Busti F., Marchi G., Ugolini S., et al. Anemia and Iron Deficiency in Cancer Patients: Role of Iron Replacement Therapy. Pharmaceuticals (Basel). 2018;11(4):94. doi: 10.3390/ph11040094.
- Lv Y., Lau W.Y., Li Y., et al. Hypersplenism: History and current status. Exp Ther Med. 2016;12(4):2377–82. doi: 10.3892/etm.2016.3683.
- Gangat N., Wolanskyj A.P. Anemia of chronic disease. Semin Hematol. 2013;50(3):232–38. doi: 10.1053/j.seminhematol.2013.06.006. Erratum in: Semin Hematol. 2014;51(2):e1.
- Weiss G., Ganz T., Goodnough L.T. Anemia of inflammation. Blood. 2019;133(1):40–50. doi: 10.1182/blood-2018-06-856500.
- Goodnough L.T., Nemeth E., Ganz T. Detection, evaluation, and management of iron-restricted erythropoiesis. Blood. 2010;116(23):4754–61. doi: 10.1182/blood-2010-05-286260.
- Jewell U.R., Kvietikova I., Scheid A., et al. Induction of HIF-1alpha in response to hypoxia is instantaneous. FASEB J. 2001;15(7):1312–14.
- Puthenparambil J., Lechner K., Kornek G. Autoimmune hemolytic anemia as a paraneoplastic phenomenon in solid tumors: A critical analysis of 52 cases reported in the literature. Wien Klin Wochenschr. 2010;122(7–8):229–36. doi: 10.1007/s00508-010-1319-z.
- Kamesaki T. [Autoimmune hemolytic anemia as a paraneoplastic syndrome associated with solid tumors]. Rinsho Ketsueki. 2015;56(7):778–84. Japanese. doi: 10.11406/rinketsu.56.778.
- Terán Brage E., Fonseca Santos M. et al. Autoimmune Haemolytic Anaemia Due to Cold Antibodies in a Renal Cancer Patient. Case Rep Oncol. 2022;15(2):507–14. doi: 10.1159/000524592.
- Lechner K., Obermeier H.L. Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases. Med (Baltimore). 2012;91(4):195–205. doi: 10.1097/MD.0b013e3182603598.
- Thomas M.R., Scully M. How I treat microangiopathic hemolytic anemia in patients with cancer. Blood. 2021;137(10):1310–17. doi: 10.1182/blood.2019003810.
- Lam R., Tarangelo N., Wang R., et al. Microangiopathic Hemolytic Anemia Is a Late and Fatal Complication of Gastric Signet Ring Cell Carcinoma: A Systematic Review and Case-Control Study. Oncologist. 2022;27(9):751–59. doi: 10.1093/oncolo/oyac093.
- Madeddu C., Neri M., Sanna E., et al. Experimental Drugs for Chemotherapy- and Cancer-Related Anemia. J Exp Pharmacol. 2021;13:593–611. doi: 10.2147/JEP.S262349.
- Vazquez L., Arnaud A. Hematological Toxicity Induced by Bone Metastasis Radiation Therapy. In: Sergi C.M., editor. Metastasis [Internet]. Brisbane (AU): Exon Publications; 2022 May 3. Chapter 8. Available from: https://www.ncbi.nlm.nih.gov/books/NBK580874. doi: 10.36255/exon-publications.metastasis.hematological-toxicity.
- Jefferies S., Rajan B., Ashley S., et al. Haematological toxicity of cranio-spinal irradiation. Radiother Oncol. 1998;48(1):23–7. doi: 10.1016/s0167-8140(98)00024-3. [PMID: 9756168].
- Weigl A., Kohler N., Monsef I., et al. Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐ stimulating agents (ESA) for cancer patients with anaemia: A systematic review and network meta-analysis. Cochrane Database Syst Rev. 2017;2017(4):CD012633. doi: 10.1002/14651858.CD012633.
- Wood P.A., Hrushesky W.J. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest. 1995;95(4):1650–59. doi: 10.1172/JCI117840.
- Kimber C., Patterson J.F., Weintraub L.R. The pathogenesis of iron deficiency anemia following partial gastrectomy. A study of iron balance. JAMA. 1967;202(10):935–8.
- Schade S.G., Cohen R.J., Conrad M.E. Effect of hydrochloric acid on iron absorption. N Engl J Med. 1968;279(13):672–74. doi: 10.1056/NEJM196809262791302.
- NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Hematopoietic Growth Factors (Version 2.2023). URL: https://www.nccn.org/professionals/physician_gls/pdf/growthfactors.pdf.
- Turner J., Parsi M., Badireddy M. Anemia. 2022 Aug 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan.
- Varlotto J., Stevenson M.A. Anemia, tumor hypoxemia, and the cancer patient. Int J Radiat Oncol Biol Phys. 2005;63(1):25–36. doi: 10.1016/j.ijrobp.2005.04.049.
- Teicher B.A., Holden S.A., al-Achi A., Herman T.S. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res. 1990;50(11):3339–44.
- Rakotomalala A., Escande A., Furlan A., et al. Hypoxia in Solid Tumors: How Low Oxygenation Impacts the «Six Rs» of Radiotherapy. Front Endocrinol (Lausanne). 2021;12:742215. doi: 10.3389/fendo.2021.742215.
- Dubsky P., Sevelda P., Jakesz R., et al. Austrian Breast and Colorectal Cancer Study Group. Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy. Clin Cancer Res. 2008;14(7):2082–87. doi: 10.1158/1078-0432.CCR-07-2068.
- Frommhold H., Guttenberger R., Henke M. The impact of blood hemoglobin content on the outcome of radiotherapy. The Freiburg experience. Strahlenther Onkol. 1998;174(Suppl. 4):31–4.
- Орлова Р.В., Гладков О.А., Кутукова С.И. и др. Практические рекомендации по лечению анемии при злокачественных новообразованиях. Злокачественные опухоли: Практические рекомендации RUSSCO. Злокачественные опухоли. 2022;12(3s2-2):19–25. [Orlova R.V., Gladkov O.A., Kutukova S.I., et al. Practical recommendations for the treatment of anemia in malignant neoplasms. Malignant Tumors: RUSSCO Practice Guidelines. Malignant tumors. 2022;12(3s2-2):19–25. (In Russ.)]. doi: 10.18027/2224-5057-2022-12-3s2-19-25.
- Aapro M., Beguin Y., Bokemeyer C., et al. ESMO Guidelines Committee. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(Suppl. 4):iv96–110. doi: 10.1093/annonc/mdx758. Erratum in: Ann Oncol. 2018;29(Suppl. 4):iv271.
- World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Published 2011. URL: https://apps.who.int/iris/bitstream/handle/10665/85839/WHO_NMH_NHD_MNM_11.1_eng.pdf?ua=1.
- Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. URL: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf.
- Aapro M., Beguin Y., Bokemeyer C., et al. SEOM clinical guidelines for anaemia treatment in cancer patients (2020). Clin Transl Oncol. 2021;23(5):931–39. doi: 10.1007/s12094-021-02580-2. Erratum in: Clin Transl Oncol. 2021;23(10):2192–93.
- Приказ Минздрава РФ от 25 ноября 2002 г. № 363 «Об утверждении Инструкции по применению компонентов крови». [Order of the Ministry of Health of the Russian Federation dated November 25, 2002 No. 363 «On Approval of the Instructions for the Use of Blood Components». (In Russ.)]. URL: http://www.consultant.ru/document/cons_doc_LAW_40315/.
- Khorana A.A., Francis C.W., Blumberg N., et al. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med. 2008;168(21):2377–81. doi: 10.1001/archinte.168.21.2377.
- Schrijvers D. Management of anemia in cancer patients: transfusions. Oncologist. 2011;16(Suppl. 3):12–8. doi: 10.1634/theoncologist.2011-S3-12.
- Gilreath J.A., Stenehjem D.D., Rodgers G.M. Diagnosis and treatment of cancer-related anemia. Am. J. Hematol. 2014;89(2):203–12. doi: 10.1002/ajh.23628.
- Tonia T., Mettler A., Robert N., et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2012;12(12):CD003407. doi: 10.1002/14651858.CD003407.pub5.
- McKoy J.M., Stonecash R.E., Cournoyer D., et al. Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion. 2008;48(8):1754–62. doi: 10.1111/j.1537-2995.2008.01749.x.
- Ludwig H., Crawford J., Osterborg A., et al. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol. 2009;27(17):2838–47. doi: 10.1200/JCO.2008.19.1130.
- Glaspy J., Crawford J., Vansteenkiste J., et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br. J. Cancer. 2010;102(2):301–15. doi: 10.1038/sj.bjc.6605498.
- Gergal Gopalkrishna Rao S.R., Bugazia S., Dhandapani T.P.M., et al. Efficacy and Cardiovascular Adverse Effects of Erythropoiesis Stimulating Agents in the Treatment of Cancer-Related Anemia: A Systematic Review of Randomized Controlled Trials. Cureus. 2021;13(9):e17835. doi: 10.7759/cureus.17835.
- Epoetin alfa. FDA label. URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103234s5363s5366lbl.pdf.
- Darbepoetin alfa. FDA label. URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/103951s5378lbl.pdf.
- Ludwig H., Aapro M., Bokemeyer C., et al. Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study. Eur J Cancer. 2009;45(9):1603–15. doi: 10.1016/j.ejca.2009.02.003.
- Petrelli F., Borgonovo K., Cabiddu M., et al. Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials. J Cancer Res Clin Oncol. 2012;138(2):179–87. doi: 10.1007/s00432-011-1072-3.
- Buchrits S., Itzhaki O., Avni T., et al. Intravenous Iron Supplementation for the Treatment of Chemotherapy-Induced Anemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Med. 2022;11(14):4156. doi: 10.3390/jcm11144156.
- Tang G.H., Dhir V., Scheer A.S., et al. Intravenous iron versus oral iron or observation for gastrointestinal malignancies: a systematic review. Eur J Gastroenterol Hepatol. 2019;31(7):799–808. doi: 10.1097/MEG.0000000000001433.
- Jurado R.L. Iron, infections, and anemia of inflammation. Clin. Infect. Dis. 1997;25(4):888–95. doi: 10.1086/515549.
- Carver P.L. The Battle for Iron between Humans and Microbes. Curr Med Chem. 2018;25(1):85–96. doi: 10.2174/0929867324666170720110049.
- Litton E., Xiao J., Ho K.M. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials. BMJ. 2013;347:f4822. doi: 10.1136/bmj.f4822.